bromocriptine has been researched along with oxidopamine in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (38.78) | 18.7374 |
| 1990's | 15 (30.61) | 18.2507 |
| 2000's | 11 (22.45) | 29.6817 |
| 2010's | 4 (8.16) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silverman, PB | 2 |
| Henke, PG; Ray, A | 1 |
| Mandel, RJ; Randall, PK | 1 |
| Kuramoto, S; Ohtsuru, K; Torigoe, R; Yoshida, M | 1 |
| Campastro, OJ; D'Anna, L; Fernández, RA; González, SA; Loidl, CF; Pecci-Saavedra, J; Soqueff, MN | 1 |
| Carruba, MO; Memo, M; Missale, C; Picotti, GB; Pizzi, M; Spano, PF | 1 |
| Boyce, S; Jenner, P; Marsden, CD | 1 |
| George, SR; Haas, DA | 1 |
| Walters, JR; Weick, BG | 1 |
| Jaton, AL; Karlsson, G; Vigouret, JM | 1 |
| Bédard, P; Di Paolo, T; Falardeau, P; Rouillard, C | 1 |
| Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB | 1 |
| Fahn, S; Hassan, MN; Higgins, D; Traub, M | 1 |
| Crowley, WR; Grosvenor, CE; Kacsoh, B; Shyr, SW | 1 |
| Martínez, JA; Milanés, MV; Vargas, ML | 1 |
| Fahn, S; Hassan, M; Jackson-Lewis, V; Traub, M; Wagner, HR | 1 |
| Duvoisin, RC; Heikkila, RE; Manzino, L | 1 |
| Carey, RJ | 1 |
| Bagli, J; Bogri, T; Voith, K | 1 |
| Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB | 1 |
| Armstrong, D; Courtney, CL; Palfai, T | 1 |
| Draganova, S; Georgiev, V; Getova, D; Lazarova, M; Markovska, V; Petkov, V; Petkova, B; Roussinov, K; Shopova, S | 1 |
| Anderson, GM; Batter, DK; Cohen, DJ; Lipton, SV; Shaywitz, BA; Teicher, MH; Young, JG | 1 |
| Asanuma, M; Kawai, M; Kohno, M; Masumizu, T; Mori, A; Ogawa, N; Tanaka, K | 1 |
| Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA | 1 |
| Dollison, A; Espinosa, A; Ferreira, M; Jackson-Lewis, V; Jiang, H; Muthane, U; Parsons, B; Przedborski, S | 1 |
| Clemens, JA; Okimura, T; Smalstig, EB | 1 |
| Abercrombie, ED; DeBoer, P; Heeringa, M; Westerink, BH | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 2 |
| Hironaka, N; Kohno, Y; Yanagita, T | 1 |
| Cumps, J; Geurts, M; Hermans, E; Maloteaux, JM | 1 |
| Barbanoj, M; Casas, M; Jané, F; Kulisevsky, J; Prat, G; Robledo, P | 1 |
| Geurts, M; Maloteaux, JM; Noël, F | 1 |
| Fukuzaki, K; Kamenosono, T; Nagata, R | 1 |
| Barbanoj, M; Casas, M; Jané, F; Prat, G; Robledo, P; Rubio, A | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Andersson, M; Cenci, MA; Lundblad, M; Westin, JE | 1 |
| Andersson, M; Cenci, MA; Kirik, D; Lundblad, M; Wierup, N; Winkler, C | 1 |
| Atsumi, M; Iga, T; Kawakami, J; Kotaki, H; Sato, H; Sawada, Y; Sugiyama, E; Yamada, Y | 1 |
| Cenci, MA; Lindgren, HS; Lundblad, M; Ohlin, KE; Rylander, D | 1 |
| Marvanova, M; Nichols, CD | 1 |
| Cortesi, R; Drechsler, M; Esposito, E; Fantin, M; Lain, F; Mariani, P; Marti, M; Menegatti, E; Morari, M; Paccamiccio, L; Sivieri, E | 1 |
| Cenci, MA; Lindgren, HS; Ohlin, KE | 1 |
| Dunnett, SB; Lane, EL | 1 |
| Asakawa, T; Ito-Yamashita, T; Namba, H; Sugiyama, K; Sun, W | 1 |
| Dunnett, SB; Lane, EL; Lelos, MJ; Murphy, EM; O'Neill, MJ | 1 |
| Chassain, C; Durif, F; Hafidi, A; Ouachikh, O; Pagès, G | 1 |
1 review(s) available for bromocriptine and oxidopamine
| Article | Year |
|---|---|
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome | 1988 |
48 other study(ies) available for bromocriptine and oxidopamine
| Article | Year |
|---|---|
Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat.
Topics: Animals; Benzazepines; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1992 |
The basolateral amygdala, dopamine and gastric stress ulcer formation in rats.
Topics: Amygdala; Animals; Bromocriptine; Cold Temperature; Dopamine; Dopamine Agents; Dopamine Antagonists; Haloperidol; Male; Microinjections; Neurons; Oxidopamine; Rats; Rats, Inbred Strains; Restraint, Physical; Stereotaxic Techniques; Stomach Ulcer; Stress, Psychological | 1991 |
Bromocriptine-induced rotation: characterization using a striatal efferent lesion in the mouse.
Topics: Animals; Bromocriptine; Corpus Striatum; Hydroxydopamines; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Stereotyped Behavior | 1990 |
Behavioral changes in 6-hydroxydopamine-treated rotation rats after delivery of various neuromodifying agents by means of a stereotactically implanted pellet to the brain.
Topics: Animals; Apomorphine; Behavior, Animal; Bromocriptine; Corpus Striatum; Dominance, Cerebral; Drug Implants; Hydroxydopamines; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra; Thyrotropin-Releasing Hormone | 1990 |
A novel, fully automated rotometer for the study of turning behavior. Comparison of results under different experimental conditions.
Topics: Animals; Apomorphine; Bromocriptine; Dopamine Agents; Female; Hydroxydopamines; Kainic Acid; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1989 |
Postsynaptic D1 and D2 dopamine receptors are present in rabbit renal and mesenteric arteries.
Topics: Adenylyl Cyclases; Animals; Benzazepines; Bromocriptine; Fenoldopam; Haloperidol; Hydroxydopamines; Mesenteric Arteries; Oxidopamine; Rabbits; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Renal Artery; Sulpiride | 1985 |
Effect of dopaminergic and alpha-adrenergic modulation on corticotropin-releasing factor immunoreactivity in rat hypothalamus.
Topics: Adrenergic alpha-Agonists; Animals; Bromocriptine; Clonidine; Corticotropin-Releasing Hormone; Dopamine Agents; Epinephrine; Haloperidol; Hydroxydopamines; Hypothalamus; Male; Methoxamine; Norepinephrine; Oxidopamine; Rats; Rats, Inbred Strains; Reserpine | 1988 |
D-1 dopamine receptor stimulation potentiates neurophysiological effects of bromocriptine in rats with lesions of the nigrostriatal dopamine pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Benzazepines; Bromocriptine; Corpus Striatum; Drug Synergism; Hydroxydopamines; Male; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Substantia Nigra | 1987 |
Dopamine D1- and D2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Benzazepines; Bromocriptine; Hydroxydopamines; Indoles; Male; Motor Activity; Oxidopamine; Phenanthridines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra; Sulpiride | 1988 |
Repeated stimulation of D-1 dopamine receptors increases the circling response to bromocriptine in rats with a 6-OHDA lesion.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Appetite Depressants; Benzazepines; Bromocriptine; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Hydroxydopamines; Locomotion; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra | 1988 |
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; Drug Administration Schedule; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra; Time Factors | 1986 |
Chronic treatment with bromocriptine induces behavioral supersensitivity in rats.
Topics: Animals; Apomorphine; Bromocriptine; Dopamine Antagonists; Humans; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Pyrrolidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1986 |
Evidence for stimulatory noradrenergic and inhibitory dopaminergic regulation of oxytocin release in the lactating rat.
Topics: Animals; Bromocriptine; Domperidone; Dopamine; Female; Hydroxydopamines; Hypothalamus; Kinetics; Lactation; Median Eminence; Norepinephrine; Oxidopamine; Oxytocin; Paraventricular Hypothalamic Nucleus; Pituitary Gland; Pregnancy; Rats; Supraoptic Nucleus | 1987 |
[Interaction of opioid peptides and the dopaminergic system in the myenteric plexus of the guniea pig ileum].
Topics: Animals; Apomorphine; Bromocriptine; Drug Interactions; Endorphins; Guinea Pigs; Haloperidol; Hydroxydopamines; Ileum; In Vitro Techniques; Myenteric Plexus; Naloxone; Oxidopamine; Receptors, Dopamine | 1987 |
The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum.
Topics: Animals; Apomorphine; Bromocriptine; Corpus Striatum; Hydroxydopamines; Kainic Acid; Male; Motor Activity; Muscle Denervation; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Stereotyped Behavior; Substantia Nigra | 1985 |
Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway.
Topics: Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Ergolines; Female; Hydroxydopamines; Oxidopamine; Parkinson Disease; Pergolide; Rats; Rats, Inbred Strains | 1982 |
Bromocriptine promotes recovery of self-stimulation in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Bromocriptine; Dextroamphetamine; Dopamine; Electrodes, Implanted; Hydroxydopamines; Motor Activity; Norepinephrine; Oxidopamine; Rats; Scopolamine; Self Stimulation | 1983 |
Troponoids. 6. Troponylpiperazines: a new class of dopamine agonists.
Topics: Animals; Bromocriptine; Cycloheptanes; Disease Models, Animal; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Structure-Activity Relationship; Tropolone | 1984 |
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Hydroxydopamines; Kinetics; Levodopa; Male; Membranes; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Stereotyped Behavior; Substantia Nigra | 1984 |
Effect of l-dopa or bromocriptine on feeding and motor behavior of rats with lesions in the globus pallidus.
Topics: Animals; Body Weight; Brain Mapping; Bromocriptine; Carbidopa; Drinking; Eating; Globus Pallidus; Hydroxydopamines; Levodopa; Male; Motor Activity; Neural Pathways; Oxidopamine; Rats; Receptors, Dopamine; Sex Factors | 1984 |
On some central effects of elymoclavine.
Topics: Animals; Bromocriptine; Catalepsy; Central Nervous System; Corpus Striatum; Ergolines; Exploratory Behavior; Haloperidol; Humans; Hydroxydopamines; Mice; Oxidopamine; Pimozide; Rats; Receptors, Dopamine; Seizures; Stereotyped Behavior; Sympathetic Nervous System | 1984 |
Effects of bromocriptine in developing rat pups after 6-hydroxydopamine.
Topics: Animals; Behavior, Animal; Brain; Bromocriptine; Dopamine; Escape Reaction; Exploratory Behavior; Female; Humans; Hydroxydopamines; Male; Motor Activity; Norepinephrine; Oxidopamine; Rats; Rats, Inbred Strains; Stereotyped Behavior | 1981 |
Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro.
Topics: Animals; Bromocriptine; Carbidopa; Corpus Striatum; Desipramine; Dopamine; Free Radical Scavengers; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine | 1994 |
On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Bromocriptine; Cocaine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Injections, Intraperitoneal; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 1993 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 1994 |
Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Bromocriptine; Male; Motor Activity; Oxidopamine; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Theobromine; Theophylline; Time Factors; Xanthines | 1993 |
Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
Topics: Administration, Oral; Animals; Bromocriptine; Corpus Striatum; Injections, Intraperitoneal; Male; Oxidopamine; Pergolide; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reserpine; Stereotyped Behavior; Substantia Nigra | 1993 |
Differential effect of systemic administration of bromocriptine and L-dopa on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats.
Topics: Acetylcholine; Animals; Bromocriptine; Corpus Striatum; Dialysis; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar | 1993 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine | 1998 |
[Comparative studies on antiparkinsonian agents, talipexole and bromocriptine, evaluated by contralateral rotational behavior in unilaterally nigral-lesioned rats].
Topics: Administration, Oral; Animals; Antiparkinson Agents; Azepines; Behavior, Animal; Benzazepines; Bromocriptine; Dopamine Antagonists; Injections, Subcutaneous; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Substantia Nigra; Sulpiride | 1998 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1999 |
Dopamine receptor-modulated [35S]GTPgammaS binding in striatum of 6-hydroxydopamine-lesioned rats.
Topics: Animals; Apomorphine; Benzazepines; Bromocriptine; Cell Membrane; Corpus Striatum; Domperidone; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Ligands; Male; Oxidopamine; Piperazines; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulfur Radioisotopes; Tritium | 1999 |
Repeated co-administration of caffeine and bromocriptine prevents tolerance to the effects of caffeine in the turning behavior animal model.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bromocriptine; Caffeine; Central Nervous System Stimulants; Dopamine Agonists; Drug Therapy, Combination; Drug Tolerance; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Rats | 1999 |
Selective destruction of nigrostriatal dopaminergic neurons does not alter [3H]-ryanodine binding in rat striatum.
Topics: Adrenergic Agents; Animals; Bromocriptine; Corpus Striatum; Dopamine; Dopamine Agonists; Male; Neuroleptic Malignant Syndrome; Neurons; Oxidopamine; Piperazines; Rats; Rats, Wistar; Ryanodine Receptor Calcium Release Channel; Substantia Nigra | 2000 |
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Catalepsy; Dopamine Agonists; Indoles; Macaca fascicularis; Male; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Reserpine; Tremor | 2000 |
Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
Topics: Animals; Bromocriptine; Caffeine; Denervation; Drug Administration Schedule; Drug Combinations; Drug Tolerance; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Rats; Rats, Sprague-Dawley; Rotation | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics | 2001 |
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Sympatholytics | 2002 |
Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D2; Rotation; Substantia Nigra | 2003 |
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
Topics: Analysis of Variance; Animals; Brain Injuries; Bromocriptine; Cell Count; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Female; Immunohistochemistry; Levodopa; Lipopolysaccharides; Movement Disorders; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA.
Topics: Animals; Bromocriptine; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cell Line; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Humans; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Quinpirole | 2007 |
Solid lipid nanoparticles as delivery systems for bromocriptine.
Topics: Absorptiometry, Photon; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Chromatography, High Pressure Liquid; Cryoelectron Microscopy; Dialysis; Drug Delivery Systems; Kinetics; Light; Lipids; Male; Microscopy, Electron; Nanoparticles; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Scattering, Radiation; Spectrophotometry, Ultraviolet; Triglycerides; X-Ray Diffraction | 2008 |
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinson Agents; Basal Ganglia; Benzazepines; Bromocriptine; Disease Models, Animal; Dopamine Agents; Dopamine D2 Receptor Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Neovascularization, Pathologic; Oxidopamine; Parkinsonian Disorders; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 2009 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors | 2010 |
Behavioral performance at early (4 weeks) and later (6 months) stages in rats with unilateral medial forebrain bundle and striatal 6-hydroxydopamine lesions.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bromocriptine; Corpus Striatum; Injections; Male; Medial Forebrain Bundle; Methamphetamine; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior | 2013 |
Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Conditioning, Operant; Dopamine Agonists; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Reaction Time | 2013 |
mGlu5 receptor antagonist blocks bromocriptine-induced conditioned place preference in bilateral mesolimbic-lesioned rat.
Topics: Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Bromocriptine; Conditioning, Operant; Desipramine; Excitatory Amino Acid Antagonists; Exploratory Behavior; Gene Expression Regulation; Male; Maze Learning; Nucleus Accumbens; Oxidopamine; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Reinforcement, Psychology; Thiazoles; Ventral Tegmental Area | 2017 |